Cinacalcet reduces plasma intact parathyroid hormone, serum phosphate and calcium levels in patients with secondary hyperparathyroidism irrespective of its severity

Clinical Nephrology

Volumn 76, Issue 3, 2011, Pages 233-243

  Frazao J M ^a   Messa, P ^b   Mellotte, G J ^c   Geiger, H ^d   Hagen, E C ^e   Quarles, L D ^f   Kerr, P G ^g   Banos A ^h   Dehmel, B ^h   Urena, P ⁱ  

^a UNIVERSITY OF PORTO   (Portugal)

^b Nephrology Division   (Italy)

^c ADELAIDE AND MEATH HOSPITAL   (Ireland)

^d GOETHE UNIVERSITY   (Germany)

^e MEANDER MEDICAL CENTER   (Netherlands)

^f UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^g MONASH MEDICAL CENTRE   (Australia)

^h AMGEN INC   (United States)

ⁱ Clinique du Landy   (France)

Author keywords

Calcimimetic; Chronic kidney disease (CKD); Cinacalcet; KDOQI guidelines; Secondary hyperparathyroidism (SHPT)

Indexed keywords

CINACALCET; PARATHYROID HORMONE; PLACEBO;

ADULT; AGED; ARTICLE; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PARATHYROID HORMONE BLOOD LEVEL; PERITONEAL DIALYSIS; PHOSPHATE BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SECONDARY HYPERPARATHYROIDISM; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; CALCIMIMETIC AGENTS; CALCIUM; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; MALE; MIDDLE AGED; NAPHTHALENES; PARATHYROID HORMONE; PHOSPHATES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; YOUNG ADULT;

EID: 80052536028     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CN106965     Document Type: Article

References (30)

1. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003; 42 (Suppl 3): S1-S201.
2. Jorna FH, Tobé TJ, Huisman RM, de Jong PE, Plukker JT, Stegeman CA. Early identification of risk factors for refractory secondary hyperparathyroidism in patients with long-term renal replacement therapy. Nephrol Dial Transplant. 2004; 19: 1168-1173.
3. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004; 15: 2208-2218.
4. Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, Young EW, Akizawa T, Akiba T, Pisoni RL, Robinson BM, Port FK. Mortality risk for dialysis patients with different levels of se rum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2008; 52: 519-530.
5. Cunningham J. Achieving therapeutic targets in the treatment of secondary hyperparathyroidism. Nephrol Dial Transplant. 2004; 19 (Suppl 5): V9-V14.
6. de Francisco AL. Medical therapy of secondary hyper parathyroidism in chronic kidney disease: old and new drugs. Expert Opin Pharmacother. 2006; 7: 2215-2224.
7. Brown AJ, Dusso AS, Slatopolsky E. Vitamin D analogues for secondary hyperparathyroidism. Nephrol Dial Transplant. 2002; 17 (Suppl 10): 10-19.
8. Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int. 2003; 63: 1483-1490.
9. Nemeth EF, Steffey ME, Hammerland LG, Hung BC, Van Wagenen BC, DelMar EG, Balandrin MF. Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci USA. 1998; 95: 4040-4045.
10. Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med. 2004; 350: 1516-1525.
11. Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB, Roger SD, Husserl FE, Klassen PS, Guo MD, Albizem MB, Coburn JW. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol. 2005; 16: 800-807.
12. Cañadillas S, Canalejo A, Santamaría R, Rodríguez ME, Estepa JC, Martín-Malo A, Bravo J, Ramos B, Aguilera-Tejero E, Rodríguez M, Almadén Y. Calcium-sensing receptor expression and parathyroid hormone secretion in hyperplastic parathyroid glands from humans. J Am Soc Nephrol. 2005; 16: 2190-2197.
13. Messa P, Macário F, Yaqoob M, Bouman K, Braun J, von Albertini B, Brink H, Maduell F, Graf H, Frazão JM, Bos WJ, Torregrosa V, Saha H, Reichel H, Wilkie M, Zani VJ, Molemans B, Carter D, Locatelli F. The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol. 2008; 3: 36-45.
14. Moe SM, Chertow GM, Coburn JW, Quarles LD, Goodman WG, Block GA, Drüeke TB, Cunningham J, Sherrard DJ, McCary LC, Olson KA, Turner SA, Martin KJ. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int. 2005; 67: 760-771.
15. de Francisco A, Suranyi M, Cunningham J, Messa P, Locatelli F, Evenepoel P, Fournier A, Gonzalez MT, Urena P, Holzer H, Brink HS, Johnson D, Zani V, Baker N, Turner SA, Drueke T. Oral cinacalcet HCl (AMG 073) for the treatment of hemodialysis patients with secondary hyperparathyroidism (HPT): results of a European/Australian phase 3 study. J Am Soc Nephrol. 2003; 14 (Suppl): 461A (abstract SA-PO742).
16. Malluche HH, Monier-Faugere MC, Wang G, Frazão JM, Charytan C, Coburn JW, Coyne DW, Kaplan MR, Baker N, McCary LC, Turner SA, Goodman WG. An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism. Clin Nephrol. 2008; 69: 269-278.
17. Shigematsu T, Akizawa T, Uchida E, Tsukamoto Y, Iwasaki M, Koshikawa S; KRN1493 Study Group. Long-term cinacalcet HCl treatment improved bone metabolism in Japanese hemodialysis patients with secondary hyperparathyroidism. Am J Nephrol. 2009; 29: 230-236.
18. Yajima A, Akizawa T, Tsukamoto Y, Kurihara S, Ito A; K Study Group. Impact of cinacalcet hydrochloride on bone histology in patients with secondary hyperparathyroidism. Ther Apher Dial. 2008; 12 (Suppl 1): S38-S43.
19. Coyne DW, Stegman MH, Azad H, Joy MS, Mischel SF, Pokroy N, Ouseph R, Gokal R, Brink HS, Jadoul M, Olson KA, Albizem MB, Klassen PS, Chertow GM. Cinacalcet HCl controls SHPT regardless of gender, race, age and geography in patients with chronic kidney disease (CKD) receiving dialysis. J Am Soc Nephrol. 2003; 14 (Suppl): 464A (abstract SA-PO754).
20. Okuno S, Ishimura E, Kitatani K, Chou H, Nagasue K, Maekawa K, Izumotani T, Yamakawa T, Imanishi Y, Shoji T, Inaba M, Nishizawa Y. Relationship between parathyroid gland size and responsiveness to maxacalcitol therapy in patients with secondary hyperparathyroidism. Nephrol Dial Transplant. 2003; 18: 2613-2621.
21. Fukagawa M, Kitaoka M, Yi H, Fukuda N, Matsumoto T, Ogata E, Kurokawa K. Serial evaluation of parathyroid size by ultrasonography is another useful marker for the long-term prognosis of calcitriol pulse therapy in chronic dialysis patients. Nephron. 1994; 68: 221-228.
22. Komaba H, Nakanishi S, Fujimori A, Tanaka M, Shin J, Shibuya K, Nishioka M, Hasegawa H, Kurosawa T, Fukagawa M. Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism. Clin J Am Soc Nephrol. 2010; 5: 2305-2314.
23. Hirai T, Nakashima A, Takasugi N, Yorioka N. Response of secondary hyperparathyroidism to cinacalcet depends on parathyroid size. Nephron Clin Pract. 2010; 114: c187-c193.
24. Coen G, Ballanti P, Bonucci E, Calabria S, Centorrino M, Fassino V, Manni M, Mantella D, Mazzaferro S, Napoletano I, Sardella D, Taggi F. Bone markers in the diagnosis of low turnover osteodystrophy in haemodialysis patients. Nephrol Dial Transplant. 1998; 13: 2294-2302.
25. Malluche HH, Mawad H, Trueba D, Monier-Faugere MC. Parathyroid hormone assays--evolution and revolutions in the care of dialysis patients. Clin Nephrol. 2003; 59: 313-318.
26. Gallieni M, Cucciniello E, D'Amaro E, Fatuzzo P, Gaggiotti A, Maringhini S, Rotolo U, Brancaccio D; Collaborating nephrologists of the CARDIALISI Study Group. Calcium, phosphate, and PTH levels in the hemodialysis population: a multicenter study. J Nephrol. 2002; 15: 165-170.
27. Young EW, Albert JM, Satayathum S, Goodkin DA, Pisoni RL, Akiba T, Akizawa T, Kurokawa K, Bommer J, Piera L, Port FK. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2005; 67: 1179-1187.
28. Takahashi N, Kojima T, Ogawa H, Ishiguro N. Correlation between parathyroid hormone, bone alkaline phosphatase and N-telopeptide of type 1 collagen in diabetic and non-diabetic haemodialysis patients. Nephrology (Carlton). 2007; 12: 539-545.
29. Malberti F, Farina M, Imbasciati E. The PTH-calcium curve and the set point of calcium in primary and secondary hyperparathyroidism. Nephrol Dial Transplant. 1999; 14: 2398-2406.
30. Yano S, Brown EM, Takase H, Wada A, Suzuki K, Kobayashi A, Sugimoto T. Calcium-corrected intact PTH: a clinically useful parameter for quantifying parathyroid function in patients undergoing hemodialysis. Nephron Clin Pract. 2010; 115: c51-c58.